تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
31.81 US$
−0.11 US$ · -0.34%
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
الإغلاق السابق
31.81 US$
−0.11 US$ · -0.34%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 31.81 US$
نطاق 52 أسبوعًا
السعر الحالي 31.81 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
2
مبالغ في سعره
المشاعر
64
صعودي
المخاطر
42
مخاطر أعلى من المعتاد
الزخم
64
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
نطاق اليوم
السعر الحالي 31.81 US$
نطاق 52 أسبوعًا
السعر الحالي 31.81 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
41.33 US$
ارتفاع محتمل بنسبة 29.93%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI63.84 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
State Street SPDR S&P Biotech ETFXBI55.11 مليون0.56%9.87 مليار USD0.35%153.77 US$+3.00%
iShares Russell 2000 ETFIWM49.6 مليون0.06%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Small-Cap ETFVB46.06 مليون0.02%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK26.39 مليون0.06%44.7 مليار USD0.05%344.74 US$+1.22%
Vanguard Extended Market ETFVXF23.28 مليون0.02%95.4 مليار USD0.05%235 US$+0.80%
iShares Biotechnology ETFIBB14.41 مليون0.14%10.82 مليار USD0.44%206.49 US$+3.00%
Dimensional - US Small Cap ETFDFAS14.31 مليون0.04%33.87 مليار USD0.31%78.35 US$+0.32%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
